Results 51 to 60 of about 20,409 (197)

HERACLIS_BLV_D: Adherence to Real‐Life Therapy With Bulevirtide in Chronic Hepatitis D

Journal of Viral Hepatitis, Volume 33, Issue 7, July 2026.
ABSTRACT Daily subcutaneous bulevirtide (BLV) 2 mg has been approved as first‐line treatment for chronic hepatitis D (CHD), but long‐term real‐world adherence data are limited. We assessed adherence rates during BLV therapy and their impact on treatment response. HERACLIS_BLV_D study (NCT05928000) included adult CHD patients initiating BLV 2 mg/day and
Dimitra Lakiotaki, Margarita Papatheodoridi, Vasilios Sevastianos, Kalliopi Zachou, Dimitrios Christodoulou, John Koskinas, Melanie Deutsch, Alexandra Alexopoulou, Ioannis Elefsiniotis, Christos Triantos, Elena Gigi, Theodoros Androutsakos, Dimitrios S. Karagiannakis, Iliana Mani, Dimitrios Dimitroulopoulos, Maria Mela, Emmanouil Sinakos, Spyros Michopoulos, Konstantinos Mimidis, Nikolaos Papadopoulos, Athanasios Kontos, Christos Veretanos, Dimitrios Lymperopoulos, George Giannoulis, Vasilios Papadimitropoulos, Evdoxia Avramopoulou, Alkistis Papatheodoridi, Spyridon Pantzios, Larisa Vasilieva, Hariklia Kranidioti, Emmanouil Koullias, Athanasios Soukovelos, Paraskevi Fytili, John Vlachogiannakos, Evangelos Cholongitas, Spilios Manolakopoulos, Ioannis Goulis, George Dalekos, George Papatheodoridis   +38 more
wiley   +1 more source

Acute pancreatitis associated with boceprevir: a case report

Brazilian Journal of Infectious Diseases, 2014
Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30–50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy,
Juliana Miguel Bilar, Roberto José Carvalho-Filho, Carolina Frade Magalhães Girardin Pimentel Mota, Patricia da Silva Fucuta, Maria Lucia Cardoso Gomes Ferraz   +4 more
doaj   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy

Advanced Science, Volume 13, Issue 34, 19 June 2026.
Engineered mesoporous silica nanoparticles (Silicasomes) enable systemic delivery of the STING agonist ADU‐S100, overcoming the instability and toxicity that limit cyclic dinucleotides to local administration. By enhancing tumor accumulation, activating systemic antitumor immunity, and remodeling the tumor immune microenvironment, these nanoparticles ...
Wenjing Zhou, Yuting Li, Xudong Sun, Honghong Yang, Xiayu Shi, Lijia Yao, Jinhong Jiang, Erli Wang, Haoyang Wang, Yi Wei, Xiangsheng Liu   +10 more
wiley   +1 more source

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4

Annals of Hepatology, 2013
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have
Juan José Urquijo, Moisés Diago, M.D., Jaume Boadas, Ramón Planas, Ricard Solá, Juan Angel del Olmo, Javier Crespo, José Carlos Erdozaín, María Dolores Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Josep M Barrera, Javier Gracia-Samaniego, Ricardo Perez, Blai Dalmau, Miguel Montoro   +16 more
doaj   +1 more source

Nanozymes for Advanced Hemoglobin‐Based Oxygen Carriers: Applications in Blood Substitution, Wound Healing, Antitumor Therapy, and Beyond

Advanced Science, Volume 13, Issue 36, 29 June 2026.
This review explores how hemoglobin‐based oxygen carriers (HBOCs) combined with nanozymes create multifunctional materials that deliver oxygen while maintaining redox homeostasis. Beyond artificial blood substitutes, these constructs enable wound healing with light‐triggered oxygen release, cancer therapy through enhanced oxygenation and reactive ...
Despoina Douka, Ana María Pablo‐Sainz‐Ezquerra, Eva Jakljevič, Niki Ktena, Leticia Hosta‐Rigau   +4 more
wiley   +1 more source

Decoding Undesirable Inflammatory Responses of Nucleic Acid‐Delivering Lipid Nanoparticles

Advanced Science, Volume 13, Issue 33, 15 June 2026.
Lipid nanoparticles (LNPs) enable efficient nucleic acid delivery, but their immunogenicity is a double‐edged sword. This review explores LNP‐driven innate and adaptive immunity, covering lipid components, endosomal escape, and nucleic acid sensing.
Ruimin Hu, Yin Dou, Chenwen Li, Yuying Mu, Huiying Ouyang, Wenhao Shen, Jianxiang Zhang   +6 more
wiley   +1 more source

Integrating Oncolytic Virus Engineering and Delivery Strategies for Enhanced Cancer Virotherapy

Aggregate, Volume 7, Issue 6, June 2026.
Integrated engineering strategies combining oncolytic virus (OV) design with advanced delivery platforms overcome biological barriers and enhance cancer virotherapy. Genetic engineering improves viral potency and selectivity, while local and systemic delivery systems promote viral protection, tumor targeting, penetration, and tumor microenvironment ...
Jiliang Zhao, Dong Wang, Lei Wang, Hongkai Zhang, Yue Sun, Dan Ding   +5 more
wiley   +1 more source

Relapse of Vogt-Koyanagi-Harada Disease during Interferon-α and Ribavirin Therapy in a Case of Chronic Viral Hepatitis C

Case Reports in Ophthalmology, 2011
A 60-year-old woman, who had been diagnosed with and treated for Vogt-Koyanagi-Harada (VKH) disease 17 years before, was receiving pegylated interferon-α and ribavirin therapy for chronic hepatitis C virus.
Miho Soma, Akira Hirata, Takamitsu Takahashi, Satoshi Okinami   +3 more
doaj   +1 more source

Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela, Ralf Gutzmer, Rudolf Stadler   +2 more
wiley   +1 more source